Indian Pharma Companies

Health min urges stakeholders to build trust in quality of Indian drugs

Union Health Minister Mansukh Mandaviya urged all the stakeholders on Sunday to steadfastly work towards building trust and confidence in the quality of Indian drugs, cosmetics and medical devices in domestic and export markets. It is of critical importance to ensure that the country's regulatory mechanisms are of impeccable standards that are sustained over time and space, Mandaviya said as he inaugurated a two-day "chintan shivir" on "Drugs: Quality Regulations and Enforcement" in Hyderabad. "How can we ensure that the confidence of the consumers of pharmaceuticals manufactured in India is upheld? I urge all the stakeholders to steadfastly work towards making the Indian drugs regulatory system among the best in the world, which could be emulated by other countries," he said. In his inaugural address, Mandaviya underlined the focus of the deliberative forum, saying, "The chintan shivir is a platform for all the stakeholders in the pharma and health sectors to deliberate on pathways

Lupin Pharma launches Lurasidone Hydrochloride Tablets in US

The generic equivalent of Latuda tablets has been launched in the US markets

Timely resolution of FDA action crucial to Indian pharma's US pipeline

Analysts say overall risks remain high for US generics business

India starts probe after Uzbekistan cough syrup deaths, Noida firm responds

According to the ministry, chemical ethylene glycol was found in a batch of syrup during laboratory tests

After Gambia, now Uzbekistan alleges Indian cold drug killed its children

Noida-based Marion Biotech's Dok-1 Max anti-cold medicine under scanner after the Central Asian nation blames it for 18 deaths

Fosun plans to sell of India's $3.8 billion drug maker Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said

Cipla Q2 PAT up 11% PAT to Rs 789 cr on strong Covid-adjusted growth rate

The company is de-risking key product Abraxane in case the Goa plant FDA issue is not cleared immediately

Pharma marketing practices: High-level committee to meet industry on Friday

The UCPMP is voluntary and there is no legal penalty for violating the code

We thrive on products that have limited competition: Top Sun Pharma execs

In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic

Lessons from Maiden: Gambia deaths raise several questions

Pharma regulatory system needs re-examination. It's not just overseas buyers of Indian pharma products who are at potential risk. Counterfeit drugs remain a major threat in the domestic market

Maiden Pharmaceuticals breaks silence on cough syrup deaths in Gambia

The pharma company Maiden Pharmaceuticals has come under scanner after 66 children died in the Gambia after consuming cough syrup produced in India

WHO issues alert for 4 India-made cough syrups; check symptoms here

WHO has asked not to use these four products until analysed by the relevant national regulatory authorities

QR codes to soon be printed on medicines to check for their authenticity

In the first phase of the 'track and trace' mechanism, the QR codes will be printed on the primary packaging like the bottle, can, jar or the strip

Indian generic formulation-makers level of capex declining: Candle Partners

Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block

Indian pharma industry eyes South American market, seeks greater access

As Global pharma majors are exiting South America post Covid, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) is looking to promote Indian pharmaceutical exports in the LAC

Govt launches 3 schemes to strengthen MSMEs in pharmaceutical sector

The government on Thursday launched three schemes to strengthen Micro, Small and Medium Enterprises (MSMEs) in the pharmaceutical sector. Union minister Mansukh Mandaviya noted that the schemes envisage technology upgradation, setting up of common research centres and effluent treatment plants in clusters for the pharma MSMEs. Small companies should be able to upgrade their facilities to global manufacturing standards, he said. The chemicals and fertilisers ministry rolled out the schemes under the banner of 'Strengthening Pharmaceuticals Industry' (SPI). "I believe the pharma MSME industry will greatly benefit from the schemes. The new schemes have many benefits that will go a long way in making the Indian pharmaceutical industry, Atma Nirbhar, more resilient and future-ready," Mandaviya, who heads both health as well as chemical and fertilisers ministries, said. The schemes provide for credit linked capital and interest subsidy for technology upgradation of MSME units in ...

Rupee at 80: Neutral impact for India's pharma industry, say experts

India's pharma sector exported drugs worth Rs 1.8 trillion in 2021-22, while APIs worth Rs 30,000 crore were imported

Cell-therapy treatment for cancer in India may come at 10% of US cost

Pharma firms and start-ups working to launch it within 2 yrs

Time for Indian pharma industry to move to value leadership: Mandaviya

Time has come for the Indian pharmaceuticals industry to move from 'volume' to 'value' leadership to capture global market and the government is committed to supporting companies with industry-friendly policies, Union minister Mansukh Mandaviya said on Saturday. Addressing an interactive session with Indian Pharmaceutical Alliance, the Minister for Chemicals & Fertilizers and Health & Family Welfare also asked the homegrown firms to learn from global best practices and develop own models to meet domestic demand while increasing international footprint. "Let us move from 'Volume' to 'Value' leadership to capture global pharmaceutical market," an official statement said, quoting Mandaviya. He further said, "It is time to accumulate knowledge from global best practices in research, manufacturing and innovation and develop our own models focused on accelerating production to meet the domestic demand while increasing our global footprint." The minister also pushed for making the .

Price is the key growth driver of Indian pharma market, shows AWACS data

Market set to grow by 2.5-5% in calendar 2022. could even hit 5% due to a strong seasonal sales such as anti-infectives, and impact of NLEM drugs price hike